The Medical Letter on Drugs and Therapeutics
ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 8/15/17: See adverse effects, last paragraph

The FDA has approved the ReShape Integrated Dual Balloon System (ReShape Medical) and the Orbera Intragastric Balloon System (Apollo Endosurgery) for up to 6 months of use in adults with a BMI of 30-40 who have not been able to maintain weight loss with a weight loss program and, for ReShape, who have at least one obesity-related comorbidity. Both devices have been available in the European Union and elsewhere for years (20 years for Orbera). Three other devices, the LAP-Band, the Realize adjustable gastric band, and the Maestro Rechargeable System, are FDA-approved for long-term treatment of obesity.1

THE DEVICES — The ReShape Dual Balloon device consists of two silicone balloons attached to a central silicone shaft. The balloons are placed in the stomach endoscopically and inflated with a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss
Article code: 1476c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian